677 – Hypertension Risk in a Large Cohort of People Living With HIV After a Switch to Dolutegravir
Background Dolutegravir (DTG) and other integrase inhibitors have been associated with an increased risk of hypertension (HTN); however, the data are conflicting and limited from low- and middle-income countries (LMICs). The weight gain threshold associated with HTN risk is also unclear, with prior studies using increases of ≥5% or ≥10%. We evaluated the association between…